Prevention and Control of Seasonal Influenza With Vaccines

Recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 Influenza Season

Lisa A. Grohskopf, MD; Sonja J. Olsen, PhD; Leslie Z. Sokolow, MSc, MPH; Joseph S. Bresee, MD; Nancy J. Cox, PhD; Karen R. Broder, MD; Ruth A. Karron, MD; Emmanuel B. Walter, MD


Morbidity and Mortality Weekly Report. 2014;63(32):691-697. 

In This Article

Abstract and Introduction


This report updates the 2013 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding use of seasonal influenza vaccines.[1] Updated information for the 2014–15 influenza season includes 1) antigenic composition of U.S. seasonal influenza vaccines; 2) vaccine dose considerations for children aged 6 months through 8 years; and 3) a preference for the use, when immediately available, of live attenuated influenza vaccine (LAIV) for healthy children aged 2 through 8 years, to be implemented as feasible for the 2014–15 season but not later than the 2015–16 season. Information regarding issues related to influenza vaccination not addressed in this report is available in the 2013 ACIP seasonal influenza recommendations.[1]

For recommendations pertaining to use of influenza vaccines in children, ACIP reviewed data on the relative efficacy and safety of LAIV and inactivated influenza vaccines (IIVs). An adapted version of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the quality of the evidence.[2] Evidence summary tables and assessment of risk and benefits are available at Information in this report reflects discussion during public meetings of ACIP on February 26, 2014, and June 25, 2014. Meeting minutes, information on ACIP membership, and information on conflicts of interest are available at Modifications were made during review at CDC to update and clarify wording. Any updates will be posted at